Ariel Pablos-Méndez

ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.

ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY.

Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY.